细胞质和核NFATc3协同促进血管光滑肌肉细胞功能障碍,并驱动大动脉动脉瘤和剖析
Xiu Liu1, Li Zhao1, Deshen Liu1
1Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Acta pharmaceutica Sinica. B
|July 23, 2025
概括
血管光滑肌细胞 (VSMCs) 中激活T细胞c3 (NFATc3) 的核因子通过降解细胞外基质驱动大动脉动脉瘤和剖析 (AAD). 抑制NFATc3可能为AAD提供一种新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 血管细胞生物学 血管细胞生物学
背景情况:
- 大动脉动脉瘤和剖析 (AAD) 涉及血管光滑肌细胞 (VSMC) 功能障碍和细胞外基质 (ECM) 退化.
- 活化T细胞c3 (NFATc3) 的核因子在VSMCs在AAD发病过程中的作用尚不清楚.
研究的目的:
- 调查在AAD进展过程中VSMCs中NFATc3的功能.
- 阐明NFATc3影响AAD发育的分子机制.
主要方法:
- 在人类和小鼠AAD组织中分析NFATc3水平.
- 生成VSMC特定的NFATc3淘汰和过度表达的小鼠模型.
- 评估ECM降解,VSMC表型和分子信号通路.
- 在体内使用卡巴米奎因向真核延长因子2 (eEF2) 的研究.
主要成果:
- 在人类和小鼠AAD中观察到细胞质和核NFATc3水平升高.
- 删除VSMC-NFATc3减轻了AAD进展,减少了ECM降解,并保留了VSMC收缩表型.
- 核NFATc3对MMP9和MMP2进行了上调,促进了ECM的降解.
- NFATc3抑制了eEF2酸化,导致VSMC的表型切换.
- 在VSMC-NFATc3过度表达的小鼠中,卡巴米治疗抑制了AAD的发展.
结论:
- VSMC-NFATc3促进了VSMC的表型切换和ECM降解,加剧了AAD.
- NFATc3代表了AAD预防和治疗的潜在治疗标.
相关概念视频
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K


